505 related articles for article (PubMed ID: 24074361)
1. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.
Kucera HR; Livingstone M; Moscoso CG; Gaikwad NW
Free Radic Res; 2013 Dec; 47(12):1016-26. PubMed ID: 24074361
[TBL] [Abstract][Full Text] [Related]
2. Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones.
Gaikwad NW; Yang L; Rogan EG; Cavalieri EL
Free Radic Biol Med; 2009 Jan; 46(2):253-62. PubMed ID: 18996184
[TBL] [Abstract][Full Text] [Related]
3. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.
den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC
Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
5. Interactions of the antioxidant enzymes NAD(P)H: Quinone oxidoreductase 1 (NQO1) and NRH: Quinone oxidoreductase 2 (NQO2) with pharmacological agents, endogenous biochemicals and environmental contaminants.
Rashid MH; Babu D; Siraki AG
Chem Biol Interact; 2021 Aug; 345():109574. PubMed ID: 34228969
[TBL] [Abstract][Full Text] [Related]
6. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.
Yan C; Dufour M; Siegel D; Reigan P; Gomez J; Shieh B; Moody CJ; Ross D
Biochemistry; 2011 Aug; 50(31):6678-88. PubMed ID: 21718050
[TBL] [Abstract][Full Text] [Related]
7. Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones.
Gaikwad NW; Rogan EG; Cavalieri EL
Free Radic Biol Med; 2007 Nov; 43(9):1289-98. PubMed ID: 17893042
[TBL] [Abstract][Full Text] [Related]
8. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.
Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S
Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6.
Jaiswal AK; Burnett P; Adesnik M; McBride OW
Biochemistry; 1990 Feb; 29(7):1899-906. PubMed ID: 1691923
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.
Dufour M; Yan C; Siegel D; Colucci MA; Jenner M; Oldham NJ; Gomez J; Reigan P; Li Y; De Matteis CI; Ross D; Moody CJ
Chembiochem; 2011 May; 12(8):1203-8. PubMed ID: 21506232
[TBL] [Abstract][Full Text] [Related]
11. NRH:quinone oxidoreductase2 (NQO2).
Long DJ; Jaiswal AK
Chem Biol Interact; 2000 Dec; 129(1-2):99-112. PubMed ID: 11154737
[TBL] [Abstract][Full Text] [Related]
12. NQO1 and NQO2 regulation of humoral immunity and autoimmunity.
Iskander K; Li J; Han S; Zheng B; Jaiswal AK
J Biol Chem; 2006 Oct; 281(41):30917-24. PubMed ID: 16905546
[TBL] [Abstract][Full Text] [Related]
13. Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.
Jamieson D; Tung AT; Knox RJ; Boddy AV
Br J Cancer; 2006 Nov; 95(9):1229-33. PubMed ID: 17031400
[TBL] [Abstract][Full Text] [Related]
14. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue.
Strassburg A; Strassburg CP; Manns MP; Tukey RH
Mol Pharmacol; 2002 Feb; 61(2):320-5. PubMed ID: 11809856
[TBL] [Abstract][Full Text] [Related]
15. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.
Celli CM; Tran N; Knox R; Jaiswal AK
Biochem Pharmacol; 2006 Jul; 72(3):366-76. PubMed ID: 16765324
[TBL] [Abstract][Full Text] [Related]
16. Molecular Pharmacology of NRH:Quinone Oxidoreductase 2: A Detoxifying Enzyme Acting as an Undercover Toxifying Enzyme.
Janda E; Nepveu F; Calamini B; Ferry G; Boutin JA
Mol Pharmacol; 2020 Nov; 98(5):620-633. PubMed ID: 32913139
[No Abstract] [Full Text] [Related]
17. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions.
Zhu H; Li Y
Cardiovasc Toxicol; 2012 Mar; 12(1):39-45. PubMed ID: 21818552
[TBL] [Abstract][Full Text] [Related]
18. The ontogeny and population variability of human hepatic dihydronicotinamide riboside:quinone oxidoreductase (NQO2).
Riches Z; Liu Y; Berman JM; Walia G; Collier AC
J Biochem Mol Toxicol; 2017 Aug; 31(8):. PubMed ID: 28346733
[TBL] [Abstract][Full Text] [Related]
19. Null association of NQO1 609C>T and NQO2 -3423G>A polymorphisms with susceptibility and prognosis of Esophageal cancer in north Indian population and meta-analysis.
Umar M; Upadhyay R; Kumar S; Ghoshal UC; Mittal B
Cancer Epidemiol; 2012 Dec; 36(6):e373-9. PubMed ID: 22770696
[TBL] [Abstract][Full Text] [Related]
20. Characterization and partial purification of microsomal NAD(P)H:quinone oxidoreductases.
Jaiswal AK
Arch Biochem Biophys; 2000 Mar; 375(1):62-8. PubMed ID: 10683249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
